Vertex Pharmaceuticals Incorporated

Shortcut’s reasoning.

Revenue $3.44bn (consensus $3.43bn): CF $3.27bn (+7.7% y/y; triple-combo +8.4% with ALYFTREK reaching 21.6% mix), CASGEVY ~$94m, JOURNAVX ~$57m and one month of PALSONIFY (~$12m) after the 1-Sep-2026 Crinetics close.

Raised FY26 revenue guide ($13.1-13.2bn, ex-Crinetics) implies ~$3.35bn for 3Q on 2025 seasonality; Vertex has beaten/raised revenue guidance, and Street revenue revisions were 13 up / 0 down, so the model sits above the guide but near consensus.

Margin headwinds were guided before consensus: non-GAAP gross margin "just under 86%" with H2 mix pressure (85.5% modelled) and opex at the high end of $5.65-5.75bn; Crinetics adds ~$40m non-GAAP opex for September.

Crinetics funding cuts net interest to ~$98m (from $121m in 2Q26): ~$8.8bn net cash out, $4.5bn term loan at ~4.6%; business-combination accounting means no AIPR&D charge inside non-GAAP EPS.

Non-GAAP tax 20.0% (guide 19.5-20.5%) and 255.1m diluted shares give EPS $4.76, $0.02 below the consensus mean of $4.78 (median $4.89, low $3.68). Starting P(beat) 0.66 from the large-cap/S&P 500 prior and 3/6 history, cut to 0.50 because the model is slightly below consensus.